Epigenetic pathways that regulate the methylation of DNA and chromatin modifications are frequently found to be dysregulated in human cancers 1 . The TET proteins ('ten-eleven translocation'; TET1-TET3) are a family of 2-oxoglutatrate-and Fe(II)-dependent dioxygenases that catalyze the oxidation of 5-methylcytosine (5mC) to sequentially generate 5-hydroxymethylcytosine (5hmC), 5-formylcytosine and 5-carboxycytosine, which are modified forms that have been shown to be intermediates in the regulation of DNA demethylation 2-4 . Decreased expression of TET proteins and loss of 5hmC have been reported in breast, colorectal, skin, stomach and lung cancers, which suggests a critical role for the maintenance of this epigenetic modification in normal cellular function 5, 6 .
Epigenetic pathways that regulate the methylation of DNA and chromatin modifications are frequently found to be dysregulated in human cancers 1 . The TET proteins ('ten-eleven translocation'; TET1-TET3) are a family of 2-oxoglutatrate-and Fe(II)-dependent dioxygenases that catalyze the oxidation of 5-methylcytosine (5mC) to sequentially generate 5-hydroxymethylcytosine (5hmC), 5-formylcytosine and 5-carboxycytosine, which are modified forms that have been shown to be intermediates in the regulation of DNA demethylation [2] [3] [4] . Decreased expression of TET proteins and loss of 5hmC have been reported in breast, colorectal, skin, stomach and lung cancers, which suggests a critical role for the maintenance of this epigenetic modification in normal cellular function 5, 6 .
Genome-wide studies have shown enrichment of 5hmC at enhancers, promoters and gene bodies of actively expressed genes 7, 8 . The presence of 5hmC may contribute to both passive DNA demethylation and active DNA demethylation in the mammalian genome. DNA methyltransferase 1 is normally required for the maintenance of methylation patterns during DNA replication and may be unable to recognize 5hmC 9 , which causes 5mC to be lost passively during cell division. The TET proteins may also actively prevent the hypermethylation of DNA and promote demethylation of DNA by a sequential process involving the deamination of 5hmC to 5hmU, mediated by the deaminases AID and APOBEC, followed by base-excision repair 4 . TET-mediated oxidation of 5hmC to 5-formylcytosine and 5-carboxylcytosine may also trigger DNA demethylation by baseexcision repair independently of deamination 10 .
The TET family was first identified because of the involvement of TET1 as a fusion partner of the gene encoding the histone methyltransferase MLL (KMT2A; called 'MLL' here) in acute myeloid leukemia (AML) 11 ; the TET1-MLL translocation event has also been detected in patients with T cell lymphoma 12 and precursor B cell acute lymphoblastic leukemia 13 . TET1 mutations are also found at a lower frequency in AML (~1%) 14 than in T cell acute lymphoblastic leukemia (~14%) 15 ; however, mutations in B cell malignancy have not been reported. Mutations in TET2 occur in ~30% of patients with myeloproliferative neoplasms and AML 16, 17 , and loss of TET2 function is associated with aberrant methylation of DNA in the hematopoietic system 18, 19 . TET1 is known to be an important regulator of 5hmC in embryonic stem cells 7, 20, 21 , as well as adult cells 4 and reprogrammed cells 22, 23 . However, loss of TET1 function in the etiology of cancer has not been investigated directly. Here we found that deletion of Tet1 in mice promoted the development of B cell lymphoma after an extended period of latency. Whole-exome sequencing of TET1-deficient tumors revealed mutations frequently found in patients with non-Hodgkin B cell lymphoma (B-NHL) [24] [25] [26] [27] ; in DNA samples from such patients, TET1 was also hypermethylated and transcriptionally silenced. Hematopoietic stem cells and progenitor cells deficient in Tet1 displayed decreased 5hmC, increased 5mC, and altered expression of VOLUME 16 NUMBER 6 JUNE 2015 nature immunology a r t i c l e s transcriptional programs involved in B cell-lineage specification, chromosome maintenance and DNA repair. Loss of TET1 promoted increased self-renewal of progenitor B cells in vitro and enhanced selfrenewal of stem cells in vivo and acted together with overexpression of the proto-oncoprotein Bcl-2 to drive B cell lymphocytosis in mice. TET1-deficient pro-B cells also displayed increased DNA damage. Our findings provide in vivo evidence of a function for TET1 as a tumor suppressor of hematopoietic malignancy and, more specifically, B cell lymphoma.
RESULTS

TET1 deficiency drives B cell malignancy in mice
We aged a cohort of TET1-deficient mice 28 and monitored their health for over 2 years. The majority of mice heterozygous (Tet1 +/− ) and homozygous (Tet1 −/− ) for TET1 deficiency remained healthy for up to 1 year of age, after which we observed diminished survival, with less than ~20% of Tet1 −/− mice remaining viable at 2 years of age, compared with ~70% of Tet1 +/+ mice (Fig. 1a) . Analysis of the peripheral blood of mice 18-24 months of age showed mild but significant lymphocytosis (P ≤ 0.05 (unpaired t-test); Fig. 1b and Supplementary Fig. 1a-d) . Upon necropsy, moribund Tet1 −/− mice often displayed severely enlarged peripheral lymph nodes (Fig. 1c) and hepato-splenomegaly (data not shown). By histological analysis, the spleen of TET1-deficient mice had disrupted architecture, with loss of delineation between the red and white pulp and extensive infiltration by atypical lymphocytes with high positivity for the proliferation marker Ki67 (Supplementary Fig. 1e) . Immunostaining of cells from the peripheral blood, lymph nodes or spleen of moribund Tet1 −/− mice revealed that the majority displayed a mature B lymphoma phenotype of SSC hi B220 + CD19 + CD43 − IgM + IgD hi−lo cells (Fig. 1d) . We also observed co-expression of the myeloid lineage marker CD11b and, in some cases, erythroid lineage markers ( Supplementary Fig. 2a,b and Supplementary Table 1) . Histological analysis of the liver, lungs and kidneys of Tet1 −/− mice revealed destructive tissue infiltration by atypical lymphocytes (Fig. 1e and Supplementary Fig. 1f,g ). The lymph nodes of Tet1 +/− and Tet1 −/− mice showed a diffuse staining pattern of lymphocytes by hematoxylin and eosin (Fig. 1f) . In addition, Tet1 −/− lymphocytes stained positive by immunohistochemistry for Bcl-6 and IRF4, which are typically expressed in mature germinal center (GC) B cells, and
Anti-IRF4
Anti-CD138 Anti-Bcl-6 a r t i c l e s negative for CD138 (syndecan-1), a marker of plasma cells (Fig. 1g) . We also observed multinucleated cells and histiocytic sarcomas in lymph nodes, spleens and infiltrated solid organs in approximately 20% of sick TET1-deficient mice (Supplementary Fig. 2c,d) . The phenotypic and malignant characteristics of TET1-deficient spleens and lymph node cells were transplantable, as they caused rapid development of disease 12 weeks after transplantation into congenic Tet1 +/+ recipient mice ( Supplementary Fig. 2e-g ). These data suggested that TET1 functioned as a tumor suppressor of hematopoietic malignancy, specifically in the B cell lineage. Table 2 ). We used germline DNA from tail tissue as the reference genome for each mouse tumor. In the coding genome, we identified >2,000 somatic mutations involving 1,785 genes, of which 157 genes were recurrently mutated in two or more tumors (Supplementary Data Sets 1-3). While the proportion of insertion-and-deletion mutations was equivalent across all tumors, the frequency of non-synonymous single-nucleotide variants (nsSNVs) differed by more than tenfold for several samples ( Fig. 2a and Supplementary Fig. 3 ). Increased numbers of nsSNVs in the highly mutated tumors corresponded to an increased frequency of base substitutions of A or T (Fig. 2b) , which has been reported before in patients with diffuse large B cell lymphoma (DLBCL) and is associated with increased frequency of mutation in genes encoding DNA-repair molecules 29 . In pooled tumor exomes, nsSNVs were predominantly missense mutations, making up 83% of all variations observed ( Fig. 2c) . Independently of mutation load, we observed more transitions than transversions ( Fig. 2d ,e) and a prevalence of C-to-T transitions in the context of GCG trinucleotides ( Fig. 2f) , which suggested a bias toward mutation of CpG cytosine residues. Several whole-genome-and exome-sequencing studies of patients with B-NHL, incorporating both DLBCL and follicular lymphoma (FL), have revealed a core set of recurrently mutated genes encoding products involved in RhoA signaling (GNA13), histone modification (KMT2D (also known as MLL2)) and B cell function (MYD88 and CD83) [24] [25] [26] . Several such genes (PIM1, CD79B and FAS) are also known targets of aberrant somatic hypermutation 30 . We found that many of the genes mutated in three or more TET1-deficient tumors (IgM − or IgM + ) corresponded with those recurrently identified in patients with B-NHL (Fig. 2g, Supplementary Fig. 4a -c and Supplementary Table 3 ). These included Kmt2d (which encodes the histone 3 Lys4 (H3K4) methyltransferase MLL2), a gene that is mutated in 30-50% of patients with DLCBL and up to 89% of patients with FL 24, 25 . In addition, we identified mutations in several genes encoding linker histones (Hist1h1c, Histh1d and Hist1h1e), along with genes encoding other histone variants and histone-modifying enzymes (Fig. 2h,i) . Mutations in HIST1H1B, HIST1H1C, HIST1H1D and HIST1H1E have been reported in up to 27% of patients with FL 26, 27 . Together, the immunophenotype and mutation spectra of TET1-deficient tumors suggested that loss of Tet1 predisposed mice to the formation of B cell lymphoma.
Hypermethylation and silencing of TET1 in human B-NHL Despite the overlapping spectrum of mutations that correspond to human B-NHL, somatic mutations of TET1 have not been reported in this disease. We investigated alternative mechanisms for the inactivation of TET1 in human B-NHL and found that TET1 was epigenetically silenced in FL (Fig. 3a) and multiple myeloma ( Supplementary  Fig. 4d ) and was transcriptionally downregulated in both DLBCL and FL (Fig. 3b) . We quantitatively analyzed the CpG methylation of TET1 for a cohort of 26 patients with FL independent of the cohort above (in Fig. 3a ) and in GC B cells from healthy donors ( Fig. 3c and Supplementary Fig. 4e ). Corresponding next-generation sequencingbased RNA sequencing (RNA-seq) analysis of TET1 expression in the same patients showed a direct correlation between hypermethylation of TET1 and decreased expression of TET1 (Fig. 3d) . These studies were consistent with our animal findings demonstrating that Tet1 −/− mice developed exclusively B cell lymphoma and with the finding that the Tet1 −/− lymphomas carried mutations in genes consistent with those found in patients with FL or DLBCL. Notably, we have found no hypermethylation of TET2 in samples from patients with B-NHL (data not shown). That finding was in agreement with the reported spectra of hematopoietic malignancies in Tet2-deficient mice, which developed mainly myeloid disease ( Supplementary Fig. 4f-h) . The greater hypermethylation of the TET1 promoter in patients with FL relative to its hypermethylation in other hematopoietic malignancies, which correlated directly with decreased TET1 expression, would suggest that, consistent with the phenotype observed in TET1-deficient mice, TET1 has a role as a tumor suppressor specifically in B cell lymphoma. 
a r t i c l e s
Loss of Tet1 acts together with Bcl2 overexpression To determine whether loss of Tet1 alters the differentiation of stem cells and progenitor cells in a cell-intrinsic manner, we performed primary transplantation of total bone marrow and secondary transplantation of purified long-term hematopoietic stem cells (LT-HSCs) (Fig. 4) . In both the primary transplantation and the secondary transplantation, CD45.2 + Tet1 −/− donor cells provided a greater contribution to the maintenance of peripheral blood reconstitution (Fig. 4a) and a significantly greater frequency of B cells 20 weeks after transplantation (Fig. 4b) than did CD45.2 + Tet1 +/+ donor cells. Together these data suggested that the chief defect in TET1-deficient mice was enhanced HSC activity, with a bias toward B cell lymphopoiesis. Given the prevalence of BCL2 translocations in patients with FL (~90%) 31 that drive overexpression of its pro-survival product Bcl-2, we investigated whether retroviral introduction of Bcl2 overexpression into Tet1 −/− Lin − Sca-1 + c-Kit + (LSK) cells would promote B lymphomagenesis. Up to 10 weeks after transplantation, we found that neither loss of Tet1 nor overexpression of Bcl2 alone had an effect on the total number of leukocytes (Fig. 4c,d) . However, the combination of loss of Tet1 and overexpression of Bcl2 drove a rapid and sustained elevation in circulating total leukocytes, specifically B lymphocytes, with little effect on the number of circulating myeloid cells (Fig. 4c,d) .
To gain further insight into the development of hematopoietic malignancies in TET1-deficient mice, we quantified the abundance of Tet1 mRNA at various stages of hematopoiesis. We found that Tet1 expression was highest in LT-HSCs, multipotent progenitors (MPPs), common lymphoid progenitors and common myeloid progenitors, then it decreased during B lineage commitment and was undetectable in immature and mature myeloid cells (Fig. 5a) . Flow cytometry of TET1-deficient bone marrow and spleen cells from young mice (1-3 months of age) showed no perturbation in hematopoietic development (Supplementary Fig. 5a,c) . However, young TET1-deficient mice with lymphoma had a lower frequency of total B220 + cells in both the spleen and bone marrow than did age-matched (young), healthy Tet1 +/+ mice, with progenitor and precursor B cells (B220 + IgM − IgD − ) making up the majority of the B cell compartment (Supplementary Fig. 5b,d-g ). In young mice, loss of Tet1 alone was sufficient to cause a decrease in the abundance of 5hmC in total bone marrow and B cells (Fig. 5b,c) . Flow cytometry of the bone marrow stem cell compartment showed no significant difference between young TET1-deficient mice with lymphoma and age-matched (Fig. 5d) . However, within the LSK compartment, staining of the SLAM ('signaling lymphocyteactivation molecule') markers CD150 and CD48 showed that LT-HSCs (CD150 + CD48 − ) were significantly lower in frequency in young, sick TET1-deficient mice than in age-matched (young), healthy Tet1 +/+ mice, whereas MPP2 cells (CD150 − CD48 + ) and lymphoid-primed MPPs (CD34 + Flt3 + ) were greater in frequency in sick TET1-deficient mice than in age-matched wild-type mice (Fig. 5e-g ). These data suggested that loss of Tet1 caused a bias toward lymphoid differentiation of HSCs and progenitor cells despite a later block in B cell maturation.
TET1 loss promotes B-lineage differentiation
In the TET1-deficient LSK compartment, the decreased frequency of LT-HSCs and increased frequency of lymphoid-primed MPPs prompted us to identify molecular signatures that define these subpopulations of LSK cells in the absence of TET1. We performed microarray analysis of RNA isolated from total LSK cells and RNA-seq analysis of purified Tet1 +/+ and Tet1 −/− LT-HSCs and MPPs (Fig. 5h-j and  Supplementary Fig. 6 ). Among genes with a greater-than-twofold difference in expression in Tet1 −/− LSK cells relative to their expression in Tet1 +/+ LSK cells, the same number were either upregulated or downregulated in the Tet1 −/− LSK cells (Fig. 5h) . By gene set-enrichment 
analysis, we observed that in total Tet1 −/− LSK cells and MPPs, there was upregulation of genes characteristically expressed by mature hematopoietic cells and, specifically, the expression profiles of B lymphoid cells and lymphomas 32, 33 (Fig. 5h,i and Supplementary  Table 4 ). This included genes encoding the transcription factors EBF1, Pax5 and IRF4 and their downstream targets VpreB, Cd79a, Igh and Blnk (Fig. 5h,i and Supplementary Table 4) , which suggested a greater differentiation bias toward the B lymphoid lineage in Tet1-deficient LSK cells than in wild-type LSK cells. Downregulated genes and gene sets that were 'negatively enriched' (that is, downregulated in Tet1 −/− cells relative to their expression in Tet1 +/+ cells) by gene set-enrichment analysis included those encoding products in pathways involved in chromosome maintenance, transcription and DNA repair (Fig. 5h,j and Supplementary Table 5) . We found downregulation of genes encoding members of histone cluster 1, including genes encoding linker histones (Hist1h1a, Hist1h1b, Hist1h1d and Hist1h1e) and genes encoding other variants of histones 2, 3 and 4 in Tet1 −/− LSK cells relative to their expression in Tet1 +/+ LSK cells; several of these (Hist1h1d, Hist1h1e, Hist1h2bc, Hist1h2bb, Hist1h3a, Hist1h3b and Hist1h3e) were also mutated in Tet1 −/− lymphoma cells (Fig. 5h,j and Supplementary Table 5 ). The higher expression of histone variants in short-term HSCs, lymphoid-primed MPPs and pre-B cells than in other hematopoietic cells (Supplementary Fig. 6d ) and their frequent mutation in B cell lymphoma indicated that these proteins might be important regulators of the development and function of B cells.
Aberrant hydroxymethylation of DNA in TET1-deficient cells
The role of TET proteins in the demethylation of DNA suggests that in the absence of these enzymes, the genome may be vulnerable to the acquisition of increased DNA methylation. We performed genomewide analysis of 5hmC and 5mC at CpG sites using HELP-GT assays (HpaII tiny fragment enrichment by ligation-mediated PCR with β-glucosyl transferase) 34 and RRBS assays (reduced representative bisulfite sequencing) 35 , respectively, in Tet1 +/+ and Tet1 −/− LSK cells. We calculated the frequency of CpG sites with differences in 5hmC or 5mC for Tet1 −/− LSK cells relative to their frequency in Tet1 +/+ LSK cells (Supplementary Fig. 7 ). We observed a global loss of 5hmC and gain in 5mC across all chromosomes (Fig. 6a-d) , with greater losses in 5hmC occurring in gene bodies (exons and introns) and intergenic regions (Supplementary Fig. 7a ) that overlapped with histone modifications (methylation of H3K4, dimethylation of H3K4 and acetylation of H3K27) characteristic of both poised enhancers and active enhancers in mouse MPPs 36 (Supplementary Fig. 7b) . Notably, only 10% of promoters exhibited losses in 5hmC, whereas the frequency of 5mC gain at promoters contributed to 27% of all hypermethylated CpGs in Tet1-deficient LSK cells compared with that of wild-type LSK cells (Fig. 6e and Supplementary Fig. 7c-e) . Using Ingenuity pathway analysis of loci that lost 5hmC in TET1-deficient LSK cells, we found that among the top 20 networks (that is, networks with the most genes with loss of 5hmC; score, 25-51; molecules in network, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and disease categories were various regulators of DNA replication, recombination and repair (Supplementary Tables 6  and 7) . Several genes encoding products involved in RhoA signaling (RhoA, Gna12 and Arghap12) and specifically base-excision repair (Apex1, Lig1 and Exo1) lost 5hmC, whereas the set of genes that displayed both loss of 5hmC and gain of 5mC showed enrichment for those encoding components of various signaling pathways, including the G protein-coupled receptor pathway (Gna14), the transforming growth factor-β pathway (Smad2, Smad3 and Smad4) and the Wnt pathway (Ctnnb1), which are known to have important roles in the homeostasis and transformation of stem cells 37, 38 ( Supplementary  Fig. 7f and Supplementary Table 6 a r t i c l e s cells, as assessed by gene set-enrichment analysis (Fig. 5i,j and Supplementary Tables 4 and 5) . These data showed that in HSCs and progenitor cells, Tet1 expression was required for maintaining the hydroxymethylation of DNA and for protection of the genome from aberrant hypermethylation of DNA.
Increased self-renewal of and DNA damage in TET1-deficient cells DLBCL and FL are characterized as diseases of mature lymphocytes that originating from GC or post-GC lymphocytes 31 . It has been shown, however, that HSCs from patients with chronic lymphocytic leukemia (CLL) display a lymphoid-lineage gene-expression bias and, in xenograft transplantation, develop into mature CLL-like B cells 39 . To assess the self-renewal potential of TET1-deficient stem and progenitor cells in vitro, we performed colony-formation assays of pro-B cells, pre-B cells and myeloid cells. Loss of Tet1 promoted a significant increase in the number of self-renewing pro-B cell colonies (Fig. 7a) , with only a moderate increase in colony formation for pre-B cells (Fig. 7b ) and no effect on myeloid colony-forming unit replating capacity (data not shown). In both pro-B cell and pre-B cell colony-forming unit cells from TET1-deficient mice, variable-diversity-joining recombination of the T cell antigen receptor appeared to be normal (data not shown). However, several genes encoding components of histone cluster 1 (with the exception of Hist1h1c) and products involved in DNA repair showed twofold lower mRNA expression, on average, in Tet1-deficient pro-B cells than in wild-type pro-B cells (Fig. 7c,d) . Consistent with their deficient expression of genes encoding products in the DNA-repair pathway, pro-B cells from Tet1 −/− mice displayed more DNA damage, with a greater percentage of cells positive for the histone variant γ-H2AX (a marker of unrepaired double-strand DNA breaks) and significantly more γ-H2AX + foci per cell, than that of their Tet1 +/+ counterparts ( Fig. 7e-g ). These data showed that TET1 deficiency had the potential to generate pre-malignant B cells at the pro-B cell stage of differentiation.
DISCUSSION
NHL constitutes a diverse array of malignancies arising from B lymphocytes or T lymphocytes of various developmental stages, immunophenotype, size, clinical presentation and disease progression 31, 40 DLBCL, FL and mantle-cell lymphoma are the most common B cell NHLs and together constitute over 60% of all NHL. Epigenetic factors have been shown to contribute to the heterogeneity of NHL, with several studies indicating the involvement of aberrant DNA methylation in disease progression. Methylation heterogeneity in FL and DLBCL increases with disease severity, and aberrant DNA methylation can be used to predict patient survival 41 .
Interestingly, B cell and T cell lymphomas with different histological subtypes are associated with distinct global DNA methylation states 42, 43 . Genes encoding key products involved in cell-cycle regulation, survival signaling and DNA repair have been shown to be hypermethylated in FL (GC tumors) relative to their methylation in mantle-cell lymphoma (pre-GC tumors) and CLL-small lymphocytic lymphoma (pre-or post-GC tumors) 44 and may reflect either the stage of normal lymphoid maturation from which these lymphomas arise or the etiology of the disease.
Methylation profiling of DNA from patients with AML led to the first observation that AML with TET2 mutation is characterized by a hypermethylation phenotype 18 . TET2 is also mutated or deleted in 6-12% of DLBCLs 45, 46 . Genome-wide profiling studies have found that patients with DLBCL with mutated TET2 also display a signature of hypermethylation not present in patients with DLBCL who have wild-type TET2 (ref. 46) . Together these findings are consistent with a role for TET proteins in generating 5hmC as an intermediate step in DNA demethylation at sites that would otherwise remain marked by 5mC. Gene silencing by DNA methylation in somatic cells is relatively stable and is compounded by repressive histone modifications and the recruitment of proteins involved in histone deacetylation. Studies have shown that DNA methylation inhibits H3K4 methylation 47 , a marker of gene activation, and is associated with H3K27 a r t i c l e s methylation 35 , a marker of repressive chromatin. Reversal of this gene silencing therefore might represent a potentially useful strategy for pharmacological intervention. Epigenetic treatments that promote gene activation at silenced chromatin include inhibitors of histone deacetylases, such as vorinostat 48 . Many phase I and phase II clinical trials are currently being conducted to expand the clinical use of such inhibitors for patients with multiple myeloma, DLBCL, myelodysplastic syndrome and AML. DNA-demethylating agents such as 5-aza-2′-deoxycytidine have been approved by the US Food and Drug Administration for use in the treatment of myelodysplastic syndrome; however, very little is known of the molecular effect of using DNAhypomethylating agents alone or in combination with inhibitors of histone deacetylases in patients with NHL. Additional DNA-methylation profiling in various lymphoma subtypes may help facilitate both diagnosis and clinical treatment. Leukemia is appreciated as a disease of stem cell origin; however, lymphoma is more commonly known as a disease of mature lymphocytes and, in the case of DLBCL and FL, a manifestation of GC or post-GC reactions 31 . However, HSCs from patients with CLL have been shown to display lymphoid-lineage gene priming and develop into mature CLL-like B cells in xenograft transplantation 39 . Clonal evolution of the same biallelic mutations in TET2 in CD34 + cells of a patient has been shown to contribute to both B cell lymphoma and AML 45 , which suggests that this patient was predisposed to malignancy from cells that retained multi-lineage differentiation potential. In a donor-recipient pair who developed FL 7 years after allogeneic transplantation of bone marrow, the donor-lymphocyte infusions were found to harbor the same rearrangement of BCL2 and the immunoglobulin heavy-chain locus and rearrangement of the variable, diversity and joining segments of the immunoglobulin heavychain locus as those in the recipient with FL 49 . While the former rearrangement was shown to be restricted to CD19 + cells, ultra-deep sequencing of CD34 + CD10 − CD19 − cells in the donor-lymphocyte infusions, containing both MPPs and HSCs, resulted in detection of 3 of 14 mutations shared by donor and recipient lymphomas, including mutations in EP300 and KLHL6 (ref. 49) , which are genes known to be recurrently mutated in patients with FL 24 . How epigenetic dysregulation in stem cells and progenitor cells may create a premalignant state or increased susceptibility to the acquisition of transforming alterations is not clear. Further deep-sequencing studies to determine the mutational status and epigenetic state of stem cells and progenitor cells from patients with DLBCL and FL might provide additional insight into the molecular ontogeny of B cell lymphoma.
Despite the evidence that loss of either TET proteins or 5hmC correlates with cancer progression, a role for TET1 as a tumor suppressor in hematopoietic malignancy had not been previously established. Our findings suggested that loss of TET1 function predisposed HSCs to malignancy and, more specifically, B cell lymphoma. Deletion of either the gene encoding TET1 (as in our study) or the gene encoding TET2 (ref. 50) in mice causes phenotypically distinct tumors affecting predominantly B lineages or myeloid lineages, respectively, which suggests non-redundant or lineage-specific roles for these enzymes during hematopoiesis or transformation. TET1 mutations in patients with hematopoietic malignancy are reported at a lower frequency than TET2 mutations; however, loss of TET1 function due to altered transcription or post-translational regulation in HSCs and progenitor cells may be an overlooked mechanism by which these cells are able to transform into lymphoma. These data suggest that hypomethylating agents could be an efficient therapy for patients with B-NHL characterized by epigenetic silencing of TET1.
METHODS
Methods and any associated references are available in the online version of the paper.
